絞り込み

16530

広告

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates.

著者 Petranova T , Boyanov M , Shinkov A , Petkova R , Intorcia M , Psachoulia E
Arch Osteoporos.2017 Dec 21 ; 13(1):1.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (48view , 0users)

Full Text Sources

Medical

Miscellaneous

Persistence with osteoporosis therapy is critical for fracture risk reduction. This observational study evaluated medication-taking behaviour of women with postmenopausal osteoporosis receiving denosumab or oral ibandronate in real-world clinical practice in Bulgaria. Compared with ibandronate, densoumab was associated with a lower discontinuation rate and greater increases in bone mineral density.
PMID: 29264666 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード